<DOC>
	<DOCNO>NCT02332590</DOCNO>
	<brief_summary>Primary Objective : To demonstrate sarilumab monotherapy superior adalimumab monotherapy respect sign symptom assess disease activity score 28 ( DAS28 ) -erythrocyte sedimentation rate ( ESR ) patient active rheumatoid arthritis ( RA ) either intolerant , consider inappropriate candidate continue treatment methotrexate ( MTX ) , least 12 week continuous treatment MTX , determine inadequate responder . Secondary Objectives : To demonstrate sarilumab monotherapy superior adalimumab monotherapy patient active RA either intolerant , consider inappropriate candidate continue treatment methotrexate ( MTX ) , least 12 week continuous treatment MTX , determine inadequate responder , respect : - Reduction sign symptom RA . - Improvement quality life assess patient report outcome questionnaire . Assessment safety tolerability sarilumab monotherapy ( include immunogenicity ) throughout study .</brief_summary>
	<brief_title>Efficacy Safety Sarilumab Adalimumab Monotherapy Patients With Rheumatoid Arthritis ( SARIL-RA-MONARCH )</brief_title>
	<detailed_description>Total study duration 310 week : Up 4 week screening period , 24 week randomize treatment phase , 276 week open label extension , 6 week post-treatment final study visit .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis ≥3 month duration . American College Rheumatology ( ACR ) Class IIII functional status . Active RA define : At least 6 66 swollen joint 8 68 tender joint , High sensitivity Creactive protein ( hsCRP ) ≥8 mg/L ESR ≥28 mm/H , DAS28ESR &gt; 5.1 . Patients per Investigator judgment either intolerant , consider inappropriate candidate continue treatment methotrexate ( MTX ) , least 12 week continuous treatment MTX , inadequate responder treat adequate MTX dose least 12 week . Exclusion criterion : Age &lt; 18 year legal age consent country study site , whichever high . Current treatment diseasemodifying antirheumatic drug ( DMARDs ) /immunosuppressive agent include MTX , cyclosporine , mycophenolate , tacrolimus , gold , penicillamine , sulfasalazine hydroxychloroquine within 2 week prior baseline ( Randomization Visit ) azathioprine , cyclophosphamide within 12 week prior baseline ( Randomization Visit ) leflunomide within 8 week prior Randomization Visit , 4 week cholestyramine washout . Treatment prior biologic agent , include antiinterleukin 6 ( IL6 ) , IL6 receptor ( IL6R ) antagonists , prior treatment Janus kinase inhibitor . Use parenteral corticosteroid intraarticular corticosteroid within 4 week prior screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>